In IMT tumours, instead, acquired resistance to ALK inhibitors has shown to occur upon clonal selection of cells harbouring the F1174L activating mutation, in virtue of the important effects this substitution has on ALK tertiary structure [12]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.